Pfizer settles U.S. marketing case dating to Wyeth conduct
WASHINGTON (Reuters) - Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.
Wyeth trained its national Rapamune sales force to promote the use of the drug in situations not approved by the U.S. Food and Drug Administration, the department said in a statement.
(Reporting by David Ingram; Editing by Gerald E. McCormick)
© Thomson Reuters 2017 All rights reserved.